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Abstract 
Background: We examined the long-term changes in the management of diabetes at a single institution in Japan.
Methods: Two repeated cross-sectional studies and a retrospective cohort study were conducted among patients 
who visited our institution between 2001 and 2013. We examined the changes in glycated hemoglobin (HbA1c) and 
glycated albumin levels, the prescription frequencies, and the daily doses of each antidiabetic agent among patients 
treated regularly for diabetes during the 13-year study period. The trends in control and treatment parameters were 
analyzed using Spearman’s rank correlation coefficient.
Results: In the first repeated cross-sectional studies, 200,298 patients had their glucose metabolism indicators 
measured, and diabetologists prescribed medications to 193, 445 patients. Of these, 170 patients were included in the 
retrospective cohort study. The patients’ diabetic control tended to improve over the study period. The mean HbA1c 
level improved from 7.9 to 7.6% (from 63 to 60 mmol/mol) (rs = −0.11, p < 0.01) in the cross-sectional study, corre-
sponding to a change from 8.2 to 7.7% (from 66 to 61 mmol/mol) (rs = −0.22, p < 0.01) in the retrospective study. The 
mean GA level improved from 22.7 to 20.7% (rs = −0.13, p < 0.01) in the cross-sectional study and from 23.5 to 21.5% 
(rs = −0.14, p < 0.01) in the retrospective study. Over the study period, prescription frequencies and daily doses of 
antidiabetic agents changed as treatment guidelines were altered.
Conclusions: The present study revealed a tendency toward long-term improvements in diabetic control, with 
changes in the prescription patterns consistent with research and guideline evidence.
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Background
The incidence of diabetes is rising globally. As of 2013, 
382 million people had the disease, with that num-
ber expected to increase to 592 million by 2035 [1]. 
In Japan, 16.2% of men and 9.2% of women either have 
or are strongly suspected of having diabetes [2]. As the 
number of patients with diabetes increases, the associ-
ated medical costs rise in tandem. In 2013, global health 
expenditure due to diabetes was estimated to be USD 548 
billion. Moreover, those costs are expected to increase to 
USD 627 billion by 2035. Consequently, diabetes is con-
sidered a serious health problem worldwide [3].
Glycated hemoglobin (HbA1c) levels are affected by 
anemia, age, and other factors, and when used in isola-
tion, they are not very accurate for monitoring diabetes 
in patients with conditions such as impaired renal func-
tion or in those who are pregnant [4–6]. Glycated albu-
min levels, which reflect blood glucose levels over the 
previous two weeks and are useful in managing diabetes 
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albumin levels are used as an indicator of diabetes man-
agement in Japan.
In 2002, intensive therapy and lowering of HbA1c 
were effective in preventing diabetic complications [10]. 
A diagnosis of metabolic syndrome that was caused by 
insulin resistance increases was focused on in 2005 [11]. 
In 2006, biguanide was designated as the first-line drug 
for diabetes treatment, and thiazolidine was added as the 
second-line drug [12]. In 2007, the importance of post-
prandial hyperglycemia management was shown [13]. In 
2012, incretin-related drugs were added as second-line 
drugs [14]. In addition, a patient-centered approach was 
recommended.
Although the diabetes management guidelines have 
been updated frequently, changes in the overall treat-
ment of diabetes and changes in the diabetes man-
agement of each patient remains unclear. Repeated 
cross-sectional analyses can observe overall tendencies of 
all patients. However, such study designs have some limi-
tations regarding the observation of the course of each 
patient. In addition, retrospective cohort analyses have 
the opposite characteristic. Therefore, we conducted two 
large-scale repeated cross-sectional studies and a single 
long-term retrospective study to address these problems.
Our aims were to characterize the effects of evolving 
diabetes management guidelines by examining long-
term changes in prescribing antidiabetic medications and 
changes in diabetic control parameters.
Methods
Study population
This article describes two repeated cross-sectional stud-
ies and a retrospective cohort study of patients who vis-
ited the Endocrinology and Metabolism Division of the 
Nippon Telegraph and Telephone Corporation (NTT) 
Medical Center, Tokyo between January 2001 and May 
2013. The Endocrinology and Metabolism Division had 
between two and five diabetologists at a time during the 
study period. They treated over 10,000 outpatients and 
approximately 200 inpatients per year in total in an urban 
area around Tokyo in Japan. The analyzed information 
included that of inpatients and outpatients.
First, we performed two repeated cross-sectional stud-
ies to examine the changes in diabetes management 
parameters and prescriptions that occurred between 
2001 and 2013. All patient identification (ID) numbers 
were coded following the data extraction so that individ-
uals could not be identified.
The repeated cross‑sectional study of diabetes management 
parameters
First, we extracted the blood test results for patients 
who had had their HbA1c or glycated albumin levels 
measured at the Endocrinology and Metabolism Divi-
sion during the study period, together with the patients’ 
ID numbers and test dates. The inclusion and exclusion 
criteria are shown in Fig.  1. The Japan Diabetes Soci-
ety (JDS) HbA1c values were measured. These values 
were converted to International Federation of Clinical 
Chemistry (IFCC) values via National Glycohemoglobin 
Standardization Program (NGSP) values using the fol-
lowing formulae: HbA1c (NGSP) (%)  =  {[HbA1c (JDS) 
(%)  ×  1.02]  +  0.25 (%)} and HbA1c (IFCC) (mmol/
mol) =  {[10.93 ×  NGSP (%)] −  23.50 (mmol/mol)} [15, 
16]. Next, using International Statistical Classification of 
Diseases and Related Health Problems (ICD)-10 codes 
[17], we excluded patients without the following diag-
noses: E10, type 1 diabetes mellitus; E11, type 2 diabetes 
mellitus; E12, malnutrition-related diabetes mellitus; E13, 
other specified diabetes mellitus; and E14, unspecified 
diabetes mellitus. To identify changes in diabetic control 
for the period from 2001 to 2013, we calculated the mean 
HbA1c levels, glycated albumin levels, or both per year.
The repeated cross‑sectional study of antidiabetic 
prescription frequency
The study of antidiabetic prescription patterns was con-
ducted similarly to the study of changes in the indicators 
of diabetic control. The inclusion and exclusion criteria 
are shown in Fig. 2. We included patients who were pre-
scribed medication by diabetologists at the Endocrinology 
and Metabolism Division between January 2001 and May 
2013 but excluded patients without ICD-10 codes E10 to 
E14. To identify trends in antidiabetic medication pre-
scriptions, we calculated the annual prescription rate and 
annual median daily dose for each antidiabetic medication, 
based on the prescription records for the study period.
The long‑term retrospective cohort study of patients 
with diabetes
This study was performed to assess the changes in dia-
betic control and prescription patterns in a group of 
patients who continued visiting the hospital for diabetic 
232 954 patients who had their HbA1c or glycated albumin levels 
(diabetes management parameters) measured by diabetologists at the 
Endocrinology & Metabolism Division between January 2001 and 
May 2013 were included.
200 298 patients were analyzed.
32 656 patients without the ICD-10 code 
from E10 to E14 were excluded.
Fig. 1 Inclusion and exclusion criteria for the repeated cross-sec-
tional study of diabetes management parameters. ICD international 
statistical classification of diseases and related health problems
Page 3 of 9Fujibayashi et al. Diabetol Metab Syndr  (2016) 8:72 
management from 2001 to 2013. The inclusion and exclu-
sion criteria are shown in Fig. 3. First, we defined patients 
who had their HbA1c levels measured at least four times 
a year and at least twice in 2013 as “visiting patients with 
diabetes.” In general, during diabetes treatment in Japan, 
HbA1c measurements are obtained once every one to 
three months, meaning that almost all patients who had 
their HbA1c levels measured at least four times a year 
could be considered to have diabetes requiring treat-
ment. From among the visiting patients with diabetes, 
we then extracted all patients who attended hospital for 
treatment of their diabetes during the 13 years from 2001 
to 2013. We calculated the mean values of each manage-
ment parameter for each year in each patient who contin-
ued to visit the hospital.
We extracted patients, from the repeated cross-sec-
tional study of antidiabetic prescriptions, whose ID num-
bers matched those of the visiting patients with diabetes. 
We then determined which antidiabetic medications 
were prescribed to these patients each year, then calcu-
lated the median daily dose of each antidiabetic medica-
tion per year per visiting patient. Finally, using the patient 
ID numbers, we combined the annual means for the dia-
betic control parameters, the antidiabetic medication 
prescription rates, and the annual median daily doses of 
antidiabetic medications. From this combined dataset, 
we estimated the trends in diabetic control parameters 
(based on the means per year), the annual prescription 
frequency per antidiabetic medication (based on the 
means per year), and the daily doses of antidiabetic medi-
cations (based on the medians per year) in patients who 
continued receiving treatment for diabetes between 2001 
and 2013.
Statistical analysis
In the repeated cross-sectional studies, trends for 
changes in diabetic control parameters and the changes 
in daily doses of antidiabetic medications were esti-
mated using Spearman’s rank correlation coefficient. For 
the control parameters, negative correlation coefficients 
were interpreted as being indicative of improvements 
in diabetic control; for the medication usage, positive 
correlation coefficients were considered to indicate an 
increase in the daily dose of an antidiabetic medication. 
Based on the data regarding the patients’ HbA1c and 
glycated albumin values, participants were divided into 
four HbA1c categories: <6% (<42  mmol/mol), 6 to <7% 
(42 to <53 mmol/mol), 7 to <8% (53 to <64 mmol/mol), 
and ≥8% (≥64  mmol/mol) (derived from the Japanese 
248 886 patients who were prescribed medications by diabetologists at the 
Endocrinology & Metabolism Division between January 2001 and May 
2013 were included.
193 445 patients were analyzed.
55 441 patients without the ICD-10 code 
from E10 to E14 were excluded.
Fig. 2 Inclusion and exclusion criteria for the repeated cross-sec-
tional study of antidiabetic prescriptions. ICD international statistical 
classification of diseases and related health problems
170 patients were analyzed
232 954 patients who had their HbA1c or glycated albumin levels (diabetes 
management parameters) measured by diabetologists at the Endocrinology & 
Metabolism Division between January 2001 and May 2013 were included.
248 886 patients who were prescribed medications by diabetologists at the Endocrinology 
& Metabolism Division between January 2001 and May 2013 were included.
204 patients who were defined as "visiting diabetes patients“ were included.
The visiting diabetes patients were defined as patients who had their HbA1c levels measured 
four times or more a year between 2001 and 2012 (and two times or more in 2013).
§ Diabetes management: The diabetes management status of the patients was inferred by 
calculating yearly mean HbA1c and/or glycated albumin levels.
204 patients: Patients who had the same identification numbers as the "visiting 
diabetes patients" from among the above-mentioned patients were included.
§ Diabetes medications: The diabetes medications status of these patients was 
inferred by calculating the yearly median doses of prescribed antidiabetic medications.
34 patients without the ICD-10 code 
from E10 to E14 were excluded.
We combined the yearly means of the diabetes management parameters and the antidiabetic medication prescription rates and 
the yearly median daily doses of each antidiabetic medication for each patient using patients’ identification numbers.
Fig. 3 Inclusion and exclusion criteria for the retrospective cohort study of visiting diabetes patients. ICD international statistical classification of 
diseases and related health problems
Page 4 of 9Fujibayashi et al. Diabetol Metab Syndr  (2016) 8:72 
guidelines) and equivalent glycoalbumin quartiles [18]. 
The annual changes in each category were evaluated 
using the Chi square test. Subsequently, trends in the 
prescription frequencies of antidiabetic medications were 
analyzed using the Cochran–Armitage test for trend. 
Annual changes in the mean diabetic control parameters, 
the median daily antidiabetic medication doses, and the 
mean antidiabetic medication prescription frequencies 
were evaluated in the retrospective cohort study using 
the same methods as for the cross-sectional studies. 
However, although HbA1c categories were created in the 
same way, glycated albumin quartiles were based on the 
mean glycated albumin levels of the retrospective cohort. 
All calculations were performed with the statistical soft-
ware JMP Pro version 11 (SAS Institute Inc., Cary, NC, 
USA). Continuous data are reported as mean  ±  stand-
ard deviation or as median values (inter-quartile range) 
[range]. p < 0.05 were considered statistically significant.
Results
The repeated cross‑sectional study of diabetic control
Table  1 shows extracted glycated hemoglobin and 
extracted glycated albumin data for changes in the 
parameters of diabetic control observed in the repeated 
cross-sectional study. An additional file shows this in 
detail (see Additional file 1). A total of 200,298 patients 
were included, of whom approximately 70% were men. 
The HbA1c levels of 199,276 patients were measured 
between 2001 and 2013, and the glycated albumin lev-
els of 160,191 were measured between 2003 and 2013. 
The mean HbA1c level tended to decrease from 7.8% 
(62  mmol/mol) in 2001 to 7.5% (58  mmol/mol) in 2013 
(rs = −0.11, p < 0.01). Regarding the four HbA1c catego-
ries, the proportion of patients with HbA1c levels  >8% 
(>64 mmol/mol) decreased from 43% in 2001 to 30% in 
2013, while the proportion of patients with HbA1c levels 
of 6 to <7% (42 to <53  mmol/mol) increased from 19% 
in 2001 to 30% in 2013. Similar to the results for HbA1c, 
the mean glycated albumin level tended to decrease from 
22.7% in 2003 to 20.7% in 2013 (rs = −0.13, p  <  0.01). 
Furthermore, the proportion of patients with glycated 
albumin levels  ≥20.7% decreased from 62% in 2003 to 
43% in 2013, while the proportion of patients with gly-
cated albumin levels <18.0% increased from 15% in 2003 
to 35% in 2013.
The repeated cross‑sectional study of antidiabetic 
prescription frequency
Table  2 shows extracted antidiabetic medication pre-
scription data for changes in the prescription frequencies 
and daily doses of antidiabetic medications. An addi-
tional file shows this in detail (see Additional file  2). In 
total, 248,886 prescriptions were identified, for which 
data on 816,666 medications and treatments were iden-
tified, but we were not able to analyze 575 prescriptions 
(0.07%). After exclusion, data for 193,445 patients were 
analyzed. For biguanides, both the prescription frequency 
(21% in 2001 and 34% in 2013) and the daily dose (met-
formin rs  =  0.36) increased. Notably, the prescription 
frequency of dipeptidyl peptidase-4 inhibitors increased 
significantly from 2% in 2010 to 38% in 2013, as did the 
daily dose (sitagliptin rs = 0.10; alogliptin rs = 0.14; and 
vildagliptin rs  =  0.19). The daily dose of α-glucosidase 
inhibitors also increased (voglibose rs =  0.30 and acar-
bose rs =  0.04). By contrast, for sulfonylureas, both the 
prescription frequency (34% in 2001 to 29% in 2013) 
and daily dose of (glimepiride rs  =  −0.38) decreased 
significantly. In addition, the daily doses of meglitinides 
decreased slightly (nateglinide rs = −0.04 and mitiglinide 
rs = −0.12). More recently, the prescription frequency of 
thiazolidine decreased from 2011 onwards.
The retrospective cohort study of visiting diabetes patients
In the retrospective study, we analyzed the data for 170 
patients who continued to visit our hospital for diabe-
tes treatment throughout the 13-year study period. We 
included patients for whom annual information was 
available about both diabetic control parameters and 
antidiabetic medication usage.
Table  3 shows extracted glycated hemoglobin and 
extracted glycated albumin data for annual changes in the 
mean values for diabetic control. An additional file shows 
this in detail (see Additional file 3). Similar to the results 
of the repeated cross-sectional studies, the mean values 
tended to decrease (HbA1c rs = −0.22, p < 0.01; glycated 
albumin rs  =  −0.14, p  <  0.01). As for the four HbA1c 
categories, the proportion of patients with HbA1c levels 
>8% (>64 mmol/mol) decreased from 62% in 2001 to 31% 
in 2013, while the proportion of patients with HbA1c 
levels of 6 to <7% (42 to <53 mmol/mol) increased from 
8% in 2001 to 27% in 2013. In addition, the proportion 
of patients with glycated albumin levels ≥22.0% fell 
from 66% in 2003 to 37% in 2013, and the proportion of 
patients with glycated albumin levels <22.0% increased 
from 35% in 2003 to 63% in 2013.
Table  4 shows extracted antidiabetic medication pre-
scription data for the prescription frequencies and 
median daily doses, calculated annually, of the antidia-
betic medications identified in the retrospective cohort. 
An additional file shows this in detail (see Additional 
file  4). The prescription frequency of dipeptidyl pepti-
dase-4 inhibitors increased from 1% in 2010 to 41% in 
2013. The median daily doses of α-glucosidase inhibi-
tors and biguanides increased per year during the study 
period (voglibose rs  =  0.26; metformin rs  =  0.28). As 
for sulfonylureas, the median daily dose (glimepiride 
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Table 1 The extracted glycated hemoglobin and extracted glycated albumin data in the first repeated cross-sectional study
Mean ± standard deviation or n (%)
NGSP National Glygohemoglobin Standardization Program, IFCC The International Federation of Clinical Chemistry and Laboratory Medicine
* Analysis results over 13 years; Additional file 1 shows this in detail
#  Using the Chi square test
a  Percentages in this column may not add up to exactly 100% because of rounding up
Year 2001 2005 2010 2013 rs* p value*
Measured HbA1c (n) 10,651 14,342 18,783 7846
HbA1c (NGSP) (%) 7.9 ± 1.4 7.9 ± 1.4 7.7 ± 1.4 7.6 ± 1.4 −0.11 <0.01
HbA1c (IFCC) (mmol/mol) 63 ± 16 63 ± 16 60 ± 15 59 ± 15
HbA1c (NGSP) groupa
 <6% (%) 615 (6) 471 (3) 935 (5) 511 (7)
 ≥6% and <7% (%) 1997 (19) 2786 (19) 5194 (28) 2367 (30)
 ≥7% and <8% (%) 3457 (33) 5238 (37) 6621 (35) 2585 (33)
 ≥8% (%) 4582 (43) 5847 (41) 6033 (32) 2383 (30) <0.01#
Year 2003 2005 2010 2013 rs* p value*
Measured glycated albumin (n) 8415 12,934 17,681 7463
Glycated albumin (%) 22.7 ± 5.3 22.5 ± 5.6 21.2 ± 5.5 20.7 ± 5.7 −0.13 <0.01
Glycated albumin quartilea
 <18% (%) 1281 (15) 2348 (18) 5173 (29) 2584 (35)
 ≥18% and <20.7% (%) 1919 (23) 3004 (23) 4501 (26) 1728 (23)
 ≥20.7% and <24.2% (%) 2487 (30) 3737 (29) 4048 (23) 1622 (22)
 ≥24.2% (%) 2728 (32) 3845 (30) 3959 (22) 1528 (21) <0.01#
Table 2 The extracted antidiabetic medication prescription data obtained in the second repeated cross-sectional study
Median (interquartile range) [range] or n (%)
α-GI α-glucosidase inhibitors, DPP4I dipeptidyl peptidase-4 inhibitors
#  Analysis results over 13 years; Additional file 2 shows this in detail
* According to the Cochran-Armitage trend test
Year 2001 2005 2010 2013 rs# p value#
n 14,996 13,976 17,561 3118
Sulfonylureas (%) 5102 (34) 4016 (29) 5142 (29) 896 (29) <0.01*
Glimepiride (n) 197 2414 4399 783
Glimepiride (mg) 3 (2, 4) [0.5, 6] 2 (1, 3) [0.5, 6] 1 (0.5, 2) [0.5, 6] 1 (0.5, 1.5) [0.5, 6] −0.38 <0.01
Biguanide (%) 3194 (21) 3633 (26) 5432 (31) 1050 (34) <0.01*
Metformin (n) 3 164 3 622 5 430 1 050
Metformin (mg) 750 (750, 750) [250, 1000] 750 (750, 750) [250, 1000] 750 (750, 750) [250, 1500] 750 (750, 1500) [250, 2250] 0.36 <0.01
Thiazolidine (%) 338 (2) 1907 (14) 6983 (40) 758 (24) <0.01*
Pioglitazone (mg) 30 (30, 30) [15, 60] 15 (15, 30) [7.5, 30] 15 (15, 30) [7.5, 45] 15 (15, 30) [7.5, 45] 0.01 0.01
α-GI (%) 2936 (20) 2696 (19) 3966 (23) 561 (18) <0.01*
Voglibose (n) 2351 2394 3390 493
Voglibose (mg) 0.6 (0.6, 0.9) [0.2, 0.9] 0.6 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.3, 0.9] 0.30 <0.01
Meglitinides (%) 654 (4) 1352 (10) 1418 (8) 155 (5) 0.45*
Nateglinide (n) 654 1275 1170 127
Nateglinide (mg) 270 (270, 270) [60, 360] 270 (180, 270) [30, 360] 270 (180, 270) [30, 360] 270 (120, 270) [60, 360] −0.04 <0.01
DPP4I (%) 0 (0) 0 (0) 361 (2) 1176 (38) <0.01*
Sitagliptin (n) 0 0 361 818
Sitagliptin (mg) 50 (50, 50) [25, 100] 50 (25, 50) [25, 100] 0.10 <0.01
Insulins (%) 3550 (24) 5085 (36) 5660 (32) 990 (32) <0.01*
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rs = −0.45) and mean prescription rate (46% in 2001 and 
35% in 2013) both decreased annually. The yearly median 
daily dose of meglitinides also decreased (nateglinide 
rs = −0.18), and the prescription frequency of thiazoli-
dine decreased from 2012 onwards.
Discussion
In the present study, we conducted two large-scale 
repeated cross-sectional studies and a long-term retro-
spective cohort study to examine the long-term changes 
in prescribing antidiabetic medications and to examine 
the associated changes in diabetic control. First, we dem-
onstrated, through changes in parameters of glycemic 
control, that diabetes management improved over the 
study period. In addition, we showed the characteristics 
of changes in antidiabetic prescribing at our institution 
over a 10-year period. To the best of our knowledge, this 
is the first large-scale, long-term observational study of 
diabetes based on electronic medical records in Japanese 
patients.
We obtained evidence that parameters of long-
term diabetic control improved, consistent with the 
results of a previous multicenter prospective study by 
the Japan Diabetes Clinical Data Management Study 
Group (JDDM), which revealed a tendency toward 
improved HbA1c levels [19]. In 2014, the JDDM had 
98 participating institutions in Japan and had approxi-
mately 74,000 registered patients with diabetes. How-
ever, other long-term interventional studies have failed 
to detect any tendency toward improvement in HbA1c 
levels [20–23]. Similar to the repeated cross-sectional 
studies carried out here, the JDDM study was also a 
repeated cross-sectional study. However, such cross-
sectional studies are limited in their ability to esti-
mate the long-term management statuses of individual 
patients, while the intervention studies were limited 
to the available methods for treating eligible patients 
and had HbA1c targets set in advance. Accordingly, 
the results of these studies cannot readily be applied to 
clinical practice.
The present research included a retrospective cohort 
study to assess changes in patients over the 13-year study 
period. In addition, we included glycated albumin levels. 
By examining glycated albumin levels, our assessment of 
changes in management was also based on two param-
eters. Therefore, the present results provide more use-
ful estimates of the long-term trends in clinical diabetes 
management.
The present study showed that there were large 
changes in the prescription of antidiabetic medica-
tions over the 13-year study period. Changes in dia-
betes management guidelines and several factors may 
Table 3 The extracted glycated hemoglobin and extracted glycated albumin data obtained in the retrospective cohort study
Mean ± standard deviation or n (%)
NGSP national glygohemoglobin standardization program; IFCC the international federation of clinical chemistry and laboratory medicine
* Analysis results over 13 years; Additional file 3 shows this in detail
#  Using the Chi square test
a Yearly mean value for each patient
b Percentages in this column may not add up to exactly 100% because of rounding up
Year 2001 2005 2010 2013 rs* p value*
Evaluated HbA1c (NGSP) (n) 170 170 170 170
HbA1c (NGSP)a (%) 8.2 ± 0.9 8.0 ± 0.9 7.9 ± 1.0 7.7 ± 1.1 −0.22 <0.01
HbA1c (IFCC)a (mmol/mol) 67 ± 10 64 ± 9 63 ± 11 60 ± 12
HbA1c (NGSP) groupb
 <6% (%) 0 (0.0) 0 (0.0) 1 (1) 1 (1)
 ≥6% and <7% (%) 14 (8) 15 (9) 21 (12) 45 (27)
 ≥7% and <8% (%) 51 (30) 73 (43) 79 (47) 72 (42)
 ≥8% (%) 105 (62) 82 (48) 69 (41) 52 (31) <0.01#
Year 2003 2005 2010 2013 rs* p value*
Evaluated glycated albumin (n) 136 170 170 168
Glycated albumina (%) 23.5 ± 3.6 22.8 ± 3.5 22.3 ± 3.9 21.5 ± 4.4 −0.14 <0.01
Glycated albumin quartileb
 <19.7% (%) 20 (15) 28 (17) 45 (27) 59 (35)
 ≥19.7% and <22.0% (%) 27 (20) 52 (31) 45 (27) 47 (28)
 ≥22.0% and <24.6% (%) 42 (31) 40 (24) 43 (25) 26 (16)
 ≥24.6% (%) 47 (35) 50 (29) 37 (22) 36 (21) <0.01#
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explain the changes seen in prescription patterns dur-
ing the study period. First, in the mid-2000s, metabolic 
syndrome and the recommendation of the guidelines 
seemed to promote prescriptions of thiazolidine and 
α-glucosidase inhibitors and increase the daily dose of 
voglibose [11–13]. Second, the daily dose of glimepiride 
and meglitinides showed a tendency to decrease around 
2010. Previous studies have shown that severe hypogly-
cemia is associated with health risks during the treat-
ment of diabetes [24–26]. It is therefore recommended 
that during pharmaceutical treatment for diabetes, treat-
ment strategies should be employed to avoid unneces-
sary hypoglycemia [14, 27]. One study on antidiabetic 
medication prescription rates in the USA showed trends 
toward increases in the prescription rates of biguanides 
and dipeptidyl peptidase-4 inhibitors, with a concur-
rent trend toward reductions in the prescription rates 
of sulfonylureas [28], consistent with the findings of the 
present study. Monotherapy with biguanides or dipep-
tidyl peptidase-4 inhibitors is associated with a lower 
risk of inducing hypoglycemia than sulfonylurea treat-
ment. Attempts to reduce the risk of hypoglycemia 
may account for similar trends in prescription rates in 
Japan and the USA. After 2010, the prescription rates 
of dipeptidyl peptidase-4 inhibitors increased, and the 
daily doses of metformin increased. On the other hand, 
the prescription rates of thiazolidine decreased. Dipep-
tidyl peptidase-4 inhibitors were introduced clinically in 
Japan in 2009, while the maximum insurance-covered 
dose of metformin was increased from 750 to 2250 mg/
day in 2010. Recent studies have also suggested that 
thiazolidine increases the risk of bladder cancer and 
has negative effects on bones [29, 30]. In 2012, dipepti-
dyl peptidase-4 inhibitors were added to the second line 
of diabetes treatment [14]. Changes in guidelines and 
these factors may explain several observed trends after 
2010. Although the tendency to increase the prescrip-
tion rates was shown in the repeated cross-sectional 
study, we were interested in the lower prescription rates 
of biguanide. We thought that this issue was due to Japa-
nese guidelines and a characteristic of Japanese patients 
with diabetes. Since the 2000s, Japanese diabetes treat-
ment guidelines recommend that physicians provide 
care in accord with an individual patient’s status. These 
guidelines do not designate the first-line drug of diabetes 
pharmacotherapy [18]. In addition, as is widely known, 
it is thought that one of the major cause of Japanese 
Table 4 The extracted antidiabetic medication prescription data obtained in the retrospective cohort study
Median (interquartile range) [range] or n (%)
α-GI α-glucosidase inhibitors, DPP4I dipeptidyl peptidase-4 inhibitors
#  Analysis results over 13 years; Additional file 4 shows this in detail
* According to the Cochran-Armitage trend test
a Yearly median daily dose for each patient
Year 2001 2005 2010 2013 rs# p value#
n 170 170 170 170
Sulfonylureas (%) 78 (46) 63 (37) 67 (39) 59 (35) 0.02*
Glimepiride (n) 12 31 54 47
Glimepiridea (mg) 3 (2, 5.625) [1, 6] 3 (2, 4) [1, 6] 1.875 (1, 3) [0.5, 6] 1 (0.5, 2) [0.5, 6] −0.45 <0.01
Biguanide (%) 78 (46) 83 (49) 84 (49) 76 (45) 0.76*
Metformin (n) 77 83 84 76
Metformina (mg) 750 (750, 750) [375, 750] 750 (750, 750) [250, 750] 750 (750, 750) [250, 1000] 750 (750, 1500) [250, 2250] 0.28 <0.01
Thiazolidine (%) 5 (3) 35 (21) 83 (49) 48 (28) <0.01*
Pioglitazonea (mg) 30 (30, 30) [30] 15 (15, 30) [7.5, 30] 15 (15, 30) [7.5, 45] 15 (15, 30) [7.5, 45] 0.06 0.16
α-GI (%) 54 (32) 56 (33) 60 (35) 43 (25) 0.30*
Voglibose (n) 43 50 52 37
Voglibosea (mg) 0.9 (0.6, 0.9) [0.4, 0.9] 0.6 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.3, 0.9] 0.26 <0.01
Meglitinides (%) 12 (7) 15 (9) 22 (13) 8 (5) 0.44*
Nateglinide (n) 12 15 19 6
Nateglinidea (mg) 270 (270, 270) [270, 270] 270 (270, 270) [60, 270] 270 (180, 270) [60, 360] 135 (90, 225) [90, 360] −0.18 0.01
DPP4I (%) 0 (0) 0 (0) 1 (1) 70 (41) <0.01*
Sitagliptin (n) 0 0 1 52
Sitagliptina (mg) 50 (50, 50) [50, 50] 50 (25, 50) [25, 100] 0.09 0.30
Insulins (%) 69 (41) 96 (57) 97 (57) 93 (55) <0.01*
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diabetes is a deficiency of insulin secretion. These factors 
may explain the low prescription rates of biguanide.
Our study had several limitations. First, we could not 
confirm whether participants had firm diagnoses of 
diabetes and visited only our institution for treatment 
over the 13 years of this study. We defined patients as 
having diabetes if they visited the Endocrinology and 
Metabolism Division, had a recorded diagnosis of E10 
to E14 according to the ICD-10, and had their HbA1c 
levels measured. However, because this was a retro-
spective study based on medical records, we do not 
know if these patients actually met the diagnostic cri-
teria for diabetes. In addition, not all patients who had 
their HbA1c levels measured may have attended our 
institution regularly for diabetes management. How-
ever, the measurement of HbA1c is not approved in 
Japan for individuals without diabetes or where there 
is no clinical suspicion of diabetes. Similarly, the pre-
scription of antidiabetic medications has not been 
approved for patients without diabetes. Therefore, we 
are confident that almost all of the participants in our 
analysis had diabetes.
Second, the causal relationships between changes in 
the use of antidiabetic medications and variations in the 
parameters of diabetic control remain unclear. Indeed, 
this was only an observational study, so we cannot infer 
which treatments improved diabetic control. We also did 
not investigate insulin prescriptions in detail. Therefore, 
further prospective studies are needed to analyze which 
factors help improve diabetic control.
Third, the results of the present study have limited 
generalizability. This was only an observational study 
based on the data from a single institution. In addition, 
our “visiting diabetes patients” included only very com-
pliant patients who had survived 13  years of diabetes, 
which introduced bias in the results. Therefore, at best, 
the results are limited in their applicability to extremely 
compliant patients with diabetes in Japan.
Conclusions
The present study revealed a tendency toward long-
term improvements in indicators of diabetic control and 
revealed that there were major changes in the prescrib-
ing frequencies of the most common antidiabetic medi-
cations at our institution. However, these changes were 
consistent with changes in guideline recommendations 
over the study period. We conclude that new antidiabetic 
medications and treatment strategies might have positive 
effects on diabetes management but that further multi-
center research is needed.
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